BE2019C544I2 - - Google Patents

Download PDF

Info

Publication number
BE2019C544I2
BE2019C544I2 BE2019C544C BE2019C544C BE2019C544I2 BE 2019C544 I2 BE2019C544 I2 BE 2019C544I2 BE 2019C544 C BE2019C544 C BE 2019C544C BE 2019C544 C BE2019C544 C BE 2019C544C BE 2019C544 I2 BE2019C544 I2 BE 2019C544I2
Authority
BE
Belgium
Prior art keywords
sub
atoms
nitrogen
formula
fused
Prior art date
Application number
BE2019C544C
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2019C544(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BE2019C544I2 publication Critical patent/BE2019C544I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
BE2019C544C 2001-07-31 2019-10-23 BE2019C544I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US38215502P 2002-05-20 2002-05-20
PCT/US2002/024212 WO2003011277A2 (fr) 2001-07-31 2002-07-30 Methodes de mobilisation de cellules souches/embryonnaires
EP02750370A EP1411918B1 (fr) 2001-07-31 2002-07-30 Methodes de mobilisation de cellules souches/embryonnaires

Publications (1)

Publication Number Publication Date
BE2019C544I2 true BE2019C544I2 (fr) 2021-07-19

Family

ID=26976666

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C544C BE2019C544I2 (fr) 2001-07-31 2019-10-23

Country Status (29)

Country Link
US (9) US6987102B2 (fr)
EP (3) EP1411918B1 (fr)
JP (2) JP5137288B2 (fr)
KR (2) KR100996378B1 (fr)
CN (2) CN102302493B (fr)
AT (1) ATE538785T1 (fr)
AU (1) AU2002318927B2 (fr)
BE (1) BE2019C544I2 (fr)
BR (1) BRPI0211570B8 (fr)
CA (1) CA2455559C (fr)
CY (4) CY1112633T1 (fr)
DK (2) DK1411918T3 (fr)
ES (2) ES2742730T3 (fr)
FR (2) FR12C0042I1 (fr)
HK (1) HK1063005A1 (fr)
HU (1) HUP0402360A2 (fr)
IL (2) IL159312A0 (fr)
LT (2) LT2371361T (fr)
LU (2) LU92033I2 (fr)
MX (1) MXPA04000982A (fr)
NL (2) NL300537I2 (fr)
NO (4) NO336989B1 (fr)
NZ (1) NZ530169A (fr)
PL (1) PL364673A1 (fr)
PT (2) PT1411918E (fr)
RU (1) RU2309741C2 (fr)
SI (2) SI1411918T1 (fr)
WO (1) WO2003011277A2 (fr)
ZA (1) ZA200400658B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100996378B1 (ko) 2001-07-31 2010-11-25 아노르메드 인코포레이티드 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
IL161784A0 (en) 2001-12-21 2005-11-20 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR101160698B1 (ko) * 2003-06-27 2012-06-28 아사히 가세이 가부시키가이샤 세포 분화 억제제, 이것을 이용하는 세포 배양 방법, 배양 배지 및 배양된 세포주
WO2005002522A2 (fr) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions et methodes pour traiter une ischemie tissulaire
US20050069553A1 (en) 2003-08-13 2005-03-31 Yi Zheng Chimeric peptides for the regulation of GTPases
EP1656156A2 (fr) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilisation de cellules hematopoietques
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (fr) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Moyens diagnostiques et therapeutiques pour maladies associees au recepteur 4 de la chimiokine cxc (cxcr4)
EP1796716A4 (fr) * 2004-08-13 2010-09-08 Anormed Inc Combinaisons de chimiokines pour mobiliser des cellules progenitrices/souches
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
JP2008519052A (ja) 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション 薬剤によるヒト遊走性細胞の合目的的挙動
ES2421447T3 (es) 2005-06-13 2013-09-02 Cleveland Biolabs Inc Métodos para proteger frente a apoptosis usando lipopéptidos
CN101365336B (zh) * 2005-08-19 2013-05-29 健赞股份有限公司 增强化疗的方法
EP2267030A1 (fr) * 2005-08-25 2010-12-29 Repair Technologies, Inc. Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
CN101389329A (zh) * 2006-02-24 2009-03-18 健赞股份有限公司 增加血流和/或促进组织再生的方法
WO2007108689A2 (fr) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Nouveau procede d'induction de la differenciation de cellules souches et progenitrices
EP2056853A1 (fr) * 2006-08-07 2009-05-13 Genzyme Corporation Thérapie combinée
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
WO2010025416A1 (fr) * 2008-08-29 2010-03-04 Genzyme Corporation Antagonistes du cxcr4 pour des lésions rénales
EP2493295A4 (fr) * 2009-10-28 2013-05-08 Ford Henry Health System Méthodes d'atténuation des lésions causées par une irradiation
CN101716167B (zh) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20150030561A1 (en) 2011-05-16 2015-01-29 Genzyme Corp. Use of CXCR4 Antagonists
WO2014152629A1 (fr) * 2013-03-15 2014-09-25 Miller Leonard B Traitement combiné pour améliorer la cicatrisation de tissu mou, la cicatrisation de greffe de tissu adipeux, la cicatrisation osseuse endochondrale et l'ostéointégration
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
CN108348606A (zh) 2015-09-18 2018-07-31 综合医院公司以麻省总医院名义经营 用于治疗癌症的抗趋除剂的局部递送
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389634B1 (fr) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
WO2017106630A1 (fr) 2015-12-18 2017-06-22 The General Hospital Corporation Polymères polyacétal, conjugués, particules et utilisations associées
WO2017112894A1 (fr) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Méthodes pour le traitement d'une maladie immunodéficiente
CA3019394A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methodes de traitement du cancer
WO2017216373A1 (fr) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron
WO2017223229A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3808748A1 (fr) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Piperidines substutues comme inhibiteurs de cxcr4
WO2018049118A1 (fr) 2016-09-09 2018-03-15 The General Hospital Corporation Protéine hsp hybride avec un agent anti-chimiorépulsif pour le traitement du cancer
US11453706B2 (en) 2016-09-09 2022-09-27 The General Hospital Corporation HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018049120A1 (fr) 2016-09-09 2018-03-15 The General Hospital Corporation Cellules présentatrices d'antigène ex vivo ou cellules t cd positives activées pour le traitement du cancer
WO2018106738A1 (fr) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations
KR20200096942A (ko) * 2017-12-06 2020-08-14 마젠타 테라퓨틱스 인코포레이티드 조혈 줄기 및 자손 세포의 동원을 위한 투여 요법
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
TWI818938B (zh) * 2017-12-19 2023-10-21 南韓商Ｇｐｃｒ醫療公司 Gpcr異聚體抑制劑及其用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021224633A1 (fr) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Traitement pour les maladies neurodégénératives
WO2023056444A1 (fr) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Procédés d'augmentation de la production de cellules progénitrices

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
EP0497926B1 (fr) 1989-10-23 1998-06-03 Nycomed Salutar, Inc. Agents chelateurs metalliques multi-sites
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
FR2672051B1 (fr) 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP0670735B1 (fr) 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripherisation de cellules souches hematopoietiques
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd 末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (fr) * 2000-05-09 2001-11-09 The University Of British Columbia Traitement antagoniste cxcr4 de cellules hematopoietiques
DK1068357T3 (da) * 1998-03-30 2011-12-12 Northwest Biotherapeutics Inc Terapeutiske og diagnostiske anvendelser baseret på CXCR-4-genets rolle i tumorgenese
AU4696899A (en) 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
CA2244554A1 (fr) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition d'une greffe par rapport a la maladie d'un hote
IL142094A0 (en) * 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
ATE315390T1 (de) * 1998-11-17 2006-02-15 Smithkline Beecham Corp Zyklische polyamine zur behandlung der thrombozytopenie
EP1016413A1 (fr) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Hormone de croissance humaine (HGH) pour stimuler la mobilisation de cellules souches hematopoietiques pluripotentes
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
AU775123B2 (en) 1999-03-24 2004-07-15 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
WO2000066112A1 (fr) * 1999-05-03 2000-11-09 Smithkline Beecham Corporation Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine
WO2001044229A1 (fr) 1999-12-17 2001-06-21 Anormed Inc. Recepteur de chemokine liant des composes heterocycliques
AU5811001A (en) 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2001094420A1 (fr) * 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
MXPA03002325A (es) 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.
CA2419224A1 (fr) 2000-09-15 2002-03-21 Anormed Inc. Composes heterocycliques se liant avec les recepteurs de chimiokines
PT1317451E (pt) 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
PL359292A1 (en) 2000-09-29 2004-08-23 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
CA2431611A1 (fr) 2001-01-23 2002-08-01 P&G-Clairol, Inc. Intermediaires primaires pour coloration capillaire oxydante
KR100996378B1 (ko) 2001-07-31 2010-11-25 아노르메드 인코포레이티드 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
IL161784A0 (en) 2001-12-21 2005-11-20 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (de) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

Also Published As

Publication number Publication date
BRPI0211570B8 (pt) 2021-05-25
ZA200400658B (en) 2005-07-27
CY1112633T1 (el) 2015-08-05
FR19C1058I1 (fr) 2019-11-22
HK1063005A1 (en) 2004-12-10
NO20040407L (no) 2004-03-19
HUP0402360A2 (hu) 2005-02-28
IL159312A0 (en) 2004-06-01
DK2371361T3 (da) 2019-08-19
FR12C0042I1 (fr) 2012-08-10
NL301031I2 (nl) 2020-07-20
ES2380009T3 (es) 2012-05-07
PT2371361T (pt) 2019-09-10
CN1561208B (zh) 2010-11-10
JP2004538303A (ja) 2004-12-24
ES2742730T3 (es) 2020-02-17
US7897590B2 (en) 2011-03-01
LT2371361T (lt) 2019-09-10
US20060193826A1 (en) 2006-08-31
IL159312A (en) 2015-05-31
LTC2371361I2 (lt) 2021-09-27
JP5137288B2 (ja) 2013-02-06
BR0211570A (pt) 2004-07-13
BRPI0211570B1 (pt) 2020-01-28
EP1411918A4 (fr) 2007-11-14
DK1411918T3 (da) 2012-04-23
RU2004105961A (ru) 2005-03-20
US20110129448A1 (en) 2011-06-02
US20170049747A1 (en) 2017-02-23
PT1411918E (pt) 2012-03-06
US20080063624A1 (en) 2008-03-13
US20130273009A1 (en) 2013-10-17
LUC00139I2 (fr) 2021-02-10
CA2455559A1 (fr) 2003-02-13
EP3632425A1 (fr) 2020-04-08
CY2019038I2 (el) 2020-05-29
SI2371361T1 (sl) 2019-10-30
EP2371361B1 (fr) 2019-08-07
CY2012017I2 (el) 2015-08-05
US7935692B2 (en) 2011-05-03
CY2019038I1 (el) 2020-05-29
LU92033I2 (fr) 2012-08-27
LU92033I9 (fr) 2019-01-03
KR100996378B1 (ko) 2010-11-25
US6987102B2 (en) 2006-01-17
WO2003011277A3 (fr) 2003-05-22
KR20090130152A (ko) 2009-12-17
WO2003011277A2 (fr) 2003-02-13
US20150246019A1 (en) 2015-09-03
NL300537I2 (fr) 2017-02-02
CY1122199T1 (el) 2020-05-29
LTPA2019018I1 (lt) 2019-12-10
US20060223180A1 (en) 2006-10-05
RU2309741C2 (ru) 2007-11-10
NL301031I1 (nl) 2020-02-05
FR19C1058I2 (fr) 2020-10-23
AU2002318927B2 (en) 2007-01-04
CA2455559C (fr) 2012-01-10
ATE538785T1 (de) 2012-01-15
NO20150674A1 (no) 2015-05-27
SI1411918T1 (sl) 2012-04-30
CN102302493B (zh) 2015-08-12
JP2008195730A (ja) 2008-08-28
NO2020003I1 (no) 2020-03-05
NO2016011I1 (no) 2016-06-10
NO344632B1 (no) 2020-02-17
MXPA04000982A (es) 2004-04-20
KR20040020075A (ko) 2004-03-06
CN102302493A (zh) 2012-01-04
EP1411918B1 (fr) 2011-12-28
US20030130250A1 (en) 2003-07-10
NZ530169A (en) 2007-04-27
CN1561208A (zh) 2005-01-05
US20190216773A1 (en) 2019-07-18
EP2371361A1 (fr) 2011-10-05
LUC00139I1 (fr) 2019-11-27
EP1411918A2 (fr) 2004-04-28
CY2012017I1 (el) 2015-08-05
PL364673A1 (en) 2004-12-13
NO336989B1 (no) 2015-12-14

Similar Documents

Publication Publication Date Title
LUC00139I1 (fr)
AP1497A (en) Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
KR920012082A (ko) Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
ES2164164T3 (es) Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
MA27576A1 (fr) Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
WO1994019343A3 (fr) Nouvelle application des composes bis-heterocycliques et les compositions pharmaceutiques en tant qu'agents anti-inflammatoires
ATE46511T1 (de) Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel.
WO1999023092A3 (fr) 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine
EP1142883A4 (fr) Nouveaux composes heterocycliques et compositions de medicaments les renfermant
AR026222A1 (es) Compuestos derivados de acido antranilico
OA09239A (fr) "Nouveaux céphèmes et procédés pour leur préparation".
WO2007106063A3 (fr) Procédés servant à accroître le débit sanguin et/ou à favoriser la régénération d'un tissu
EA200000527A2 (ru) Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
EP1057829A4 (fr) Dérivés de la pyrimidine condensés et compositions pharmaceutiques les contenant
ES8605524A1 (es) Procedimiento para preparar tieno- y furo-(2,3-c)-pirroles